Thrombolytics and Myocardial Infarction

Cardiovascular Therapeutics

Volumn 30, Issue 2, 2012, Pages

  Kunadian, Vijayalakshmi ^a   Gibson, C Michael ^b  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Acute myocardial infarction; Streptokinase; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FIBRINOLYTIC THERAPY; GROUPS BY AGE; HEART EJECTION FRACTION; HEART REINFARCTION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; STROKE; SURVIVAL;

FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 84858233860     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00239.x     Document Type: Review

References (70)

1. Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung and Blood disease. 2009. Ref Type: Internet Communication.
2. Kerrick J. Coronary obstruction. JAMA 1912;59:2015-2020.
3. Fletcher AP, Alkjaersign N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958;71:287-296.
4. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-585.
5. Koren G, Weiss AT, Hasin Y, et al. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med 1985;313:1384-1389.
6. Lew AS, Laramee P, Cercek B, Rodriguez L, Shah PK, Ganz W. The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction. Circulation 1985;72:1053-1058.
7. Simoons ML, Serruys PW, van den BM, et al. Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands. Lancet 1985;2:578-582.
8. Hillis LD, Borer J, Braunwald E, et al. High dose intravenous streptokinase for acute myocardial infarction: Preliminary results of a multicenter trial. J Am Coll Cardiol 1985;6:957-962.
9. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
10. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
11. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
12. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-154.
13. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: II. Nature of the reaction. J Exp Med 1934;60:255-267.
14. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: I. Isolation and characterization of fibrinolysin. J Exp Med 1934;60:239-254.
15. Tillett WS, Edwards LB, Garner RL. Fibrinolytic activity of hemolytic streptococci. The development of resistance to fibrinolysis following acute hemolytic streptococcus infections. J Clin Invest 1934;13:47-78.
16. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485-502.
17. Christensen LR, Macleod CM. A proteolytic enzyme of serum: Characterization, activation and reaction with inhibitors. J Gen Physiol 1945;28:559-583.
18. Sherry S, Tillett WS, Read CT. The use of streptokinase-streptodornase in the treatment of hemothorax. J Thorac Surg 1950;20:393-417.
19. Cathie IA. Streptomycin-streptokinase treatment of tuberculous meningitis. Lancet 1949;1:441.
20. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
21. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
22. Baigent C, Collins R, Appleby P, et al.; for The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998;316:1337-1343.
23. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
24. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
25. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997;337:1124-1130.
26. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985;312:932-936.
27. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
28. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-1914.
29. Lincoff AM, Califf RM, Van de WF, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002;288:2130-2135.
30. Smalling RW, Bode C, Kalbfleisch J, et al.; for the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.
31. Bode C, Smalling RW, Berg G, et al.; for The RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
32. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 1995;346:329-336.
33. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674.
34. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-356.
35. Cannon CP, Gibson CM, McCabe CH, et al.; for the Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Circulation 1998;98:2805-2814.
36. Van de WF, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999;137:786-791.
37. Van de WF, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722.
38. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
39. Dundar Y, Hill R, Dickson R, Walley T. Comparative efficacy of thrombolytics in acute myocardial infarction: A systematic review. QJM 2003;96:103-113.
40. Llevadot J, Guigliano RP. Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction. Expert Opin Investig Drugs 2000;9:2689-2694.
41. Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005-2013.
42. Spiecker M, Windeler J, Vermeer F, et al. Thrombolysis with saruplase versus streptokinase in acute myocardial infarctionFive-year results of the PRIMI trial. Am Heart J 1999;138(3 Pt 1):518-524.
43. Tebbe U, Michels R, Adgey J, et al.; for the Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS Equivalence Trial. J Am Coll Cardiol 1998;31:487-493.
44. Bar FW, Meyer J, Vermeer F, et al. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol 1997;79:727-732.
45. Vanderschueren S, Barrios L, Kerdsinchai P, et al.; for The STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-2049.
46. Armstrong PW, Burton J, Pakola S, et al. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS II). Am Heart J 2003;146:484-488.
47. Cannon CP, Bahit M, Haugland JM, et al. Under-utilization of evidence based medications in acute ST elevation myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI 9) registry. Crit Pathways Cardiol 2002;1:44-52.
48. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993;270:1211-1216.
49. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000;283:2686-2692.
50. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996;348:771-775.
51. Newby LK, Rutsch WR, Califf RM, et al.; for the GUSTO-1 Investigators. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996;27:1646-1655.
52. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global use of strategies to open occluded coronary arteries. Circulation 1995;92:2811-2818.
53. Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998;129:597-604.
54. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001;104:1229-1235.
55. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996;94:1826-1833.
56. Weaver WD, Litwin PE, Martin JS, et al.; for The MITI Project Group. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991;18:657-662.
57. Mauri F, Gasparini M, Barbonaglia L, et al. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol 1989;63:1291-1295.
58. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): An open, prospective, randomised, multicentre trial. Lancet 2008;371:559-568.
59. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009;360:2705-2718.
60. Cantor WJ, Fitchett D, Borgundvaag B, et al. Rationale and design of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Am Heart J 2008;155:19-25.
61. Wijeysundera HC, You JJ, Nallamothu BK, Krumholz HM, Cantor WJ, Ko DT. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: A meta-analysis of contemporary randomized controlled trials. Am Heart J 2008;156:564-572.
62. Bohmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010;55:102-110.
63. Bohmer E, Arnesen H, Abdelnoor M, Mangschau A, Hoffmann P, Halvorsen S. The NORwegian study on DIstrict treatment of ST-elevation myocardial infarction (NORDISTEMI). Scand Cardiovasc J 2007;41:32-38.
64. Rentrop KP, Blanke H, Karsch KR, et al. Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979;2:354-363.
65. Ben-Ami R, Sheinman G, Yedgar S, et al. Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability. Thromb Res 2002;105:487-492.
66. Woo KS, Armiger LC, White HD, Norris RM. Can streptokinase produce beneficial effects additional to coronary recanalization? Quantitative microvascular analysis of critically injured reperfused myocardium. Microvasc Res 2000;60:8-20.
67. Sezer M, Oflaz H, Goren T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007;356:1823-1834.
68. Kelly RV, Crouch E, Krumnacher H, Cohen MG, Stouffer GA. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: Initial experience with intracoronary tenecteplase. Catheter Cardiovasc Interv 2005;66:327-332.
69. Abbas AE, Brewington SD, Dixon SR, Boura JA, Grines CL, O'Neill WW. Intracoronary fibrin-specific thrombolytic infusion facilitates percutaneous recanalization of chronic total occlusion. J Am Coll Cardiol 2005;46:793-798.
70. Kushner FG, Hand M, Smith SC, Jr., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-2241.